For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.

Educational information

This educational video is part of a series of 4 videos with the theme: Clinical Updates in Management of Cardiovascular Risk.

Educational objectives are:

• To review the epidemiology and current guidelines on the diagnosis, management, and treatment of patients at increased CV risk
• To understand the medical need for intensive risk interventions in patients at high CV risk, including diabetes
• To discuss new concepts in cardiovascular risk management including earlier and more intensive intervention and integrate scientific evidence from key clinical trials into practice
• To explore the role of new risk calculation models for cardiovascular risk estimation and communication

Faculty

Professor Kees Hovingh, MD - Internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and

visiting professor at Imperial college in London, UK

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Pfizer